Summer Sale
50% off Premium Yearly
Opinions Don Lato
Gilead Sciences Inc.GILDCOMMENTJan 24, 2017
Don LatoStock price when the opinion was issued
As of Jun 17, 2026. Market Open.
You might be interested:
It's a biopharma which as a group did very well last year. Compare that to the smaller biotechs which have not done well the past 3 years. This year, biopharma and staples have underperformed. This boasts a high free cash flow yield and has a great product cycle coming.
In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky.
Has long owned this, because it's a value stock and keeps raising its dividend.
Brian Belski
Jim Lebenthal;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
This has been a big disappointment over the last year. They’ve been hit on a couple of fronts. On their hepatitis C drug package, they have almost run out of the easy patients and the growth rate has slowed tremendously. They still have a very good pipeline in terms of HIV drugs, and also trying to build up an oncology pipeline. Stock trades at very, very low multiples, 7 or 8 times earnings. There is not going to be a lot of growth. Because of some of their high priced drugs, they really are in the target of Trump and drug pricing in the US.